BioLargo's $38M Cap vs. a Portfolio It Says Is Worth $70M on a Bad Day
A shareholder town hall, a brand-new oil-sands venture, and a company still paying for the Pooph collapse
BLGO · Earnings Call · 2026-09-10
BioLargo's $38M Cap vs. a Portfolio It Says Is Worth $70M on a Bad Day
Not an earnings call — a fireside chat with a battle-scarred pitch
BioLargo did not host a conventional quarterly call. It ran a shareholder town hall, and CEO Dennis Calvert opened by conceding the mood: “We know it's been a hard season. And so everyone is anxious to really get some good information.” — Dennis Calvert, Chief Executive Officer (CEO) · 2026-09-10 The format itself is a tell. When a microcap leans on a fireside Q&A rather than a tightly scripted report, it is usually selling a story as much as a quarter.
The tape agrees with the pain. The stock is down 31.6% over the last 90 days and sits roughly 91% below its 2014 peak, with a full-history return of -85.7%. The operating numbers reinforce it: Total revenue fell to $1M, down 55% year-over-year and 78% below the 2024Q3 peak. Operating and net income are both roughly -$4M.
Two specific events drove the year, and Calvert named both, starting with the failure of the Pooph consumer brand that carried the company's odor-control technology. He framed the damage bluntly:
We also took a financial hit on the way out the door with close to a $4 million write-down. And so that's a pretty powerful combination coming against the company.
The second was a delay in Clyra Medical, the wound-care subsidiary, whose spend is now consolidated. The Pooph business loss, he said, "overwhelms" the good news — namely that the engineering unit and remaining product lines actually grew sequentially. That is a real point, but it is buried under a consolidated loss.
What is genuinely new: Tu Nipi and the oil sands circle
The freshest thing in this report is a brand-new venture. Tu Nipi topped the company's keyword set for the quarter — a name that did not exist in its prior trajectory — formed to attack oil sands produced water (OSPW). Calvert reached back fifteen years: “We formed this venture with Tu Nipi, and it's an extraordinary team of people, small but mighty, certainly well connected.” — Dennis Calvert, Chief Executive Officer (CEO) · 2026-09-10 The pitch is scale — 1.4 to 1.8 billion cubic meters of affected water — paired with an alliance with Aquatech, a global water player operating in 32 countries.
This is a company-unique theme, not sector boilerplate. Nothing in the global keyword set or in the other companies that reported this week overlaps meaningfully with Alberta oil-sands water treatment. If it works, it is BioLargo's alone.
There is one place where the company brushes a global wave that is currently cooling: data-center water recycling. BioLargo flagged commercial pilots tied to data centers, arguing utilities face noise, PFAS discharge and water-consumption pressure. But the global tape shows the data-center trade fading at the margin — "AI data centers" is among the sharpest 30-day decliners, with dozens of names negative. Riding a theme that is cooling is a riskier proposition than riding one that is heating up.
The Pooph hole and the consumer-products relaunch
Management is explicit that the recovery bet is a self-owned brand. The old Pooph brand generated about $125M in lifetime gross sales and peaked near a $60M annual run-rate, of which roughly $15M flowed to BioLargo as a supply-chain partner. The new consumer products arm, BioLargo CPG, targets about half that, launching in October. The critical change is ownership: previously they supplied; now they own the brand and capture gross. The pitch leans on a reference site of proven chemistry and a proven playbook.
The catch is capital. This is a company whose effective net cash has fallen to $2M, down 50% year-over-year, against a parent overhead Calvert pegs tightly: “The parent company basically needs about $250,000 a month to run its current level of operations.” — Dennis Calvert, Chief Executive Officer (CEO) · 2026-09-10 The funding model — push dilution to the subsidiaries — is central to the story. The battery company, Cellinity, has raised at a $33–34M valuation and is being shopped higher.
The sum-of-parts math versus the tape
Calvert made his most concrete argument as arithmetic: a price-to-revenue multiple of roughly 9x applied against what he calls a floor. Clyra Medical carries an internal mark near $100M; BioLargo owns about 48%, so roughly $40M. Add Cellinity at $33–34M and, he argues, the business is "worth at least $70M on a bad day" against a ~$34M cap.
That claim deserves the same skepticism the company itself invites. Subsidiary marks are private-transaction prices, not liquidity events, and the same "we don't control the timing" problem keeps recurring. On the prior call, pressed on when the Clyra deal would close, Calvert had said: “We don't actually know. That's really the better way to say it. It could. It could be next month. It could be a couple of months.” — Dennis Calvert, CEO · 2024-04-02 The battery unit has likewise carried a standing capital plan — “$7.5 million Series A, $40 million Series B” — Dennis Calvert, CEO · 2025-11-15 — that has yet to land. And shareholders keep asking the same question they asked two years ago: “When do you expect to stop the dilution of shares?” — Brian Loper, Host/Investor Relations or Communications · 2024-04-02The read: BioLargo is a long-duration, option-value portfolio wrapped in a balance sheet that is running lean. The genuinely new items — Tu Nipi, the oil-sands re-entry, the October CPG launch — are company-unique and potentially material. But the confirming numbers are not here yet; what the fundamentals show is a business whose revenue has round-tripped, whose cash is thin, and whose thesis rests almost entirely on financing events outside its control. The story got louder this quarter. The proof is still one or two closings away.